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Available online 24 April 2012Abstract Cardiomyocytes (CMs) and mesenchymal stem cells (MSCs) are important cell types for cardiac repair post
myocardial infarction. Here we proved that both CMs and MSCs can be simultaneously generated from human induced
pluripotent stem cells (hiPSCs) via a pro-mesoderm differentiation strategy. Two hiPSC lines, hiPSC (1) and hiPSC (2) were
generated from human dermal fibroblasts using OCT-4, SOX-2, KLF-4, c-Myc via retroviral-based reprogramming. H9 human
embryonic stem cells (hESCs) served as control. CMs and MSCs were co-generated from hiPSCs and hESCs via embryoid body-
dependent cardiac differentiation protocol involving a serum-free and insulin-depleted medium containing a p38 MAPK
inhibitor, SB 203580. Comparing to bone marrow and umbilical cord blood-derived MSCs, hiPSC-derived MSCs (iMSCs) expressed
common MSC markers and were capable of adipogenesis, osteogenesis and chondrogenesis. Moreover, iMSCs continuously
proliferated for more than 32 population doublings without cellular senescence and showed superior pro-angiogenic and wound
healing properties. In summary, we generated a large number of homogenous MSCs in conjunction with CMs in a low-cost and
efficient one step manner. Functionally competent CMs and MSCs co-generated from hiPSCs may be useful for autologous
cardiac repair.
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88 H. Wei et al.Cardiac cell therapy requires not only functional cardiomyo-
cytes (CMs), but also pro-angiogenic cell lineages such as
mesenchymal stem/stromal cells (MSCs) for effective cardiac
repair. However, clinical application of CMs has been hampered
by the lack of autologous and large quantity of functional
human CMs. On the other hand, MSCs derived from adult tissues
such as bonemarrow have shown therapeutic potential (Amado
et al., 2005; Schuleri et al., 2009). However, clinical
application with adult MSCs from the elderly (Fan et al., 2010;
Kasper et al., 2009; Yu et al., 2011) and patients (Heeschen et
al., 2004; Nie et al., 2010) are limited due to their poor self-
renewal potential and functional competency. Therefore, an
alternative source of MSCs is imperative for successful
therapeutic applications together with CMs in autologous
cardiac cell therapy.
Human pluripotent stem cells (hPSCs), including human
embryonic stem cells (hESCs) and human induced pluripotent
stem cells (hiPSCs) are capable of differentiating into both CMs
and MSCs. However, although hESCs are capable of generating
functional CMs and MSCs, their wide-spread clinical applica-
tions have been hampered by immunoreactivity and ethical
issues. The introduction of iPSCs by Yamanaka and colleagues
(Takahashi and Yamanaka, 2006) may provide a more tenable
solution. Patient-specific iPSCs have been generated from
somatic cells of patients with various ages and diseases (Park et
al., 2008; Takahashi et al., 2007; Yu et al., 2007). Like ES cells,
iPSCs can be preserved and repeatedly used to generate many
cell lineages such as CMs (Xu et al., 2002; Zhang et al., 2009)
and MSCs (Lian et al., 2007, 2010) without reduced capacity as
normally expected in adult tissue derived cells.
Currently, hPSC-CMs and hPSC-MSCs are separately derived
from disparate mesodermal differentiation protocols which
are tedious and time-consuming.We hypothesize that CMs and
MSCs, both of mesoderm origin; can be generated concurrent-
ly from hPSCs via embryoid body (EB) formation with a pro-
mesodermal condition. As cardiac differentiation indicates a
mesodermal diversion from pluripotency of hiPSCs, MSCs co-
obtained could be less of tumorigenic concern, which makes
this MSC generation procedure simple, low-cost and efficient.
In this study, with a modified pro-mesodermal differentia-
tion protocol, we repeatedly co-generated high quality of CMs
and MSCs from individual EBs derived from hiPSCs. Both cell
types showed functional characteristics that are promising for
autologous application in cardiac cell therapy.Results
Generation and characterization of hiPSCs
Concordance with our previous report of virus-free iPSC
(Mehta et al., 2011), the current viral approach of
reprogramming dermal fibroblasts gave rise to iPSC colonies
with typical ESC-like morphology in approximately 18 days
post retroviral transduction. Two hiPSC clones, hiPSC (1) and
hiPSC (2) were selected for this study. Their doubling rates
were comparable to the similarly maintained H9 hESC cell
line. Further, immunocytochemistry staining confirmed that
all hiPSC clones expressed pluripotent stem cell markers,
OCT4, SSEA4, TRA1-60 and TRA-1-81 (Fig. 1a). Moreover,
their endogenous expression of OCT-4, SOX-2, KLF-4 and c-
Myc were validated by RT-PCR (Fig. 1b). Those hiPSC cloneswere confirmed to carry the genome incorporation of the
transgenes in retroviral vectors but do not express those 4
transgenes (Supplementary Fig. 1). Further, the pluripo-
tency of hiPSCs were confirmed by teratoma formation in
vivo with phenotypes of three germ layers consisting gut
epithelium (endoderm), smooth muscle (mesoderm) and
neuroepithelial rosette (ectoderm) following renal capsule
implant in SCID mice at week 12 (Fig. 1c). Both hiPSC (1) and
hiPSC (2) showed normal karyotype that was similar to the
well characterized H9 hESC line (Fig. 1d).
Co-generation of CMs and MSCs from hiPSCs
EBs were created from undifferentiated colonies of hiPSCs (1)
and (2) and H9 hESCs and differentiated towards cardiomyo-
cytes following a modified cardiac differentiation protocol
which involves cardiomyogenic medium (CARM) plus a specific
p38-MAPK inhibitor SB 203580 (hereby named CARM/SB
protocol). After 15 days of cardiac differentiation, ~50% of
EBs survived and were plated between 15 and 21 days. Both of
the contracting (containing functional cardiomyocytes) and
non-contracting EBs gave raise to homogenous outgrowth of
MSC-like cell population that rapidly migrated from the
attached EBs. With the contracting EBs, the beating cell
clusters were microdissected out to isolate cardiomyocytes.
Fig. 2A presents a graphical demonstration for generating CMs
(Fig. 2Ae) and MSCs (Fig. 2Af) following the CARM/SB protocol.
To test parallel presence of both CMs and MSCs in EB and their
spatial relationship, immunoflurescent (IF) staining of Day 15
EBs showed that MSCs present in all EBs (Figs. 2Ba and Bb)
while CMs were clearly presented only in the contracting EBs
(Fig. 2Ba) but not non-contracting EBs. CMs and MSCs do not
co-localize (Fig. 2Ba).
In addition, the percentages of CMs and MSCs in contracting
EBs were quantified (Fig. 2C). First, and the percentage of CMs
and MSCs in contracting EBs were estimated by immunofluo-
rescent staining dissociated cells with cardiac specificmarkers
(Myosin light chain: MLC) and MSC marker (CD44), counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI) (Figs. 2a,
b). The percentage of CMs were 22.03% while MSCs were
around 45.72%. Second, the percentage of MSCs were
measured by Flow Cytometry assay of cells dissociated from
contracting and non-contracting EBs. The markers varied from
59% (CD105) to 78% (CD90) and 81% (CD29). The variation in
the proportion of different MSC surface markers determined
with cells dissociated from EBs may reflect the heterogeneity
of cell lineages in EBs as some markers may express in non-
MSCs.
Following the CARM/SB protocol, 3 lines of iMSCs were
generated from each line of hPSCs in three independent
differentiation experiments.
hiPSC-CMs showed structural and functional
characteristics of cardiomyocytes
All cardiomyocytes tested in this study were ~5 weeks post
differentiation. Cardiomyocytes dissociated from contracting
cell clusters showed specific cardiacmarkers including cardiac
sarcomeric α-actinin, β-myosin heavy chain (β-MHC) and Titin
(Fig. 3A). There is no appreciable difference in proportion of
three subtypes of cardiomyocytes including ventricular-like
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Figure 1 Characterization of hiPSCs. A: Immunofluorescent staining of iPSC (1) with antibodies against Oct-4, SSEA-4 (63×
objective, scale bars: 20 µm), Tra-1-60, and Tra-1-81 (40× objective, scale bars: 100 µm). B: RT-PCR for the expression of endogenous
genes OCT-4, SCX-2, c-Myc and KLF-4 in iPSC (1) and hiPSC (2) with H9 hESCs and the parental neonatal dermal fibroblast (FB) as
control. C: Hematoxylin and eosin staining of teratoma derived from iPSC (1) in NOD-SCID mice after 12 weeks. Characteristic tissue
structures representing 3-germ layers (indicated by arrows) are: glandular structure for endoderm (C1), smooth muscle tissue for
mesoderm (C2) and neural epithelia for ectoderm (C3), scale bar: 200 µM. D: Karyotype of H9 hESC, hiPSC (1) and hiPSC (2).
89One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells(V), atrial-like (A), and nodal-like (N) cardiomyocytes between
hiPSC-CMs and hESC-CMs (Fig. 3C) determined by character-
istic action potential traces (Fig. 3B). It was also noted, as
shown in Fig. 3D, that the cardiac differentiation efficiency
(measured as the % of contracting EBs) for hiPSC (1) and (2)
(20–30%) was lower than hESCs (50%).iMSCs meet the criteria for human MSCs with robust
self renewal potential and superior biological function
MSC lines derived from hPSCs were subjected to charac-
terizations. MSCs derived from the contracting EBs of hiPSC
(1) and hiPSC (2) and hESC (H9) are named as iMSC (1),
90 H. Wei et al.iMSC (2) and H9 hESC-MSCs respectively. All experiments
were repeated at least for three times. The data of iMSC
(1) is presented in most of the figures. Human bone marrow
MSCs (BM-MSCs) and umbilical cord blood MSCs (CB-MSCs)
were adopted as control in some of the characterization
studies.Figure 2 Co-generation of CMs and MSCs from hiPSC by a modifie
from hiPSC by a modified CARM/SB method. Top– flow chart of the
graphical demonstration of the process for co-generating hiPSC-CMs
(b): EBs formed in suspension culture on Day 2 after differentiation. (
(d): Contracting/non-contracting EB-aggregates plated after Day 15–
contracting and non-contracting EB. Scale bar for a–d, e1 and f: 200
from contracting (a) and non-contracting (b) EBs derived from hi
(positive for myosin light chain or MLC) and arrows indicate MSCs (po
EBs. (a) CMs in dissociated EBs were quantified by immunofluores
quantified by immunofluorescent staining against CD44. (c) hiPSC–MiMSCs expressed typical MSC surface markers
In contrast to the parental hPSC lines which showed SSEA-4,
TRA-1-60 and TRA-1-80 surface pluripotent marker expres-
sion, EB-derived MSCs expressed no SSEA-4, TRA-1-60 and
TRA-1-80 right after being isolated from EBs (passage 2 or
P2) (Fig. 4A). Expectedly, from early (P2) to late passagesd CARM/SB method. A: Diagram for co-generating CMs and MSCs
process for co-generating hiPSC-CMs and hiPSC-MSCs. Bottom–
and hiPSC-MSCs. (a): Undifferentiated colonies of hiPSCs on MEF.
c): EB-aggregates in suspension 15–21 days after differentiation.
21. (e) CMs derived from contracting EBs. (f): MSCs derived from
µm. Scale bar for e2: 100 µm. B: Identification of CMs and MSCs
PSCs. Magnification: 20×. Arrowheads indicate cardiomyocytes
sitive for CD44). C: Quantification of CMs and MSCs in dissociated
cent staining against β-MHC. (b) MSCs in dissociated EBs were
SCs in dissociated EBs quantified by flow cytometry assay.
Figure 2 (continued)
Figure 3 Characterization of hiPSC-CMs. A: Cardiomyocytes immunofluorescently stained with cardiac markers. Scale bar: 30 µM.
B: Cardiac action potential (AP) recorded on single hiPSC-CM by whole cell patch-clamp assay. All three subtypes of cardiomyocytes
were identified by unique AP patterns. C: Proportion of each subtype of cardiomyocytes in the hPSC lines examined. D: Cardiac
differentiation efficiency (% contracting EB /total EB aggregates) determined among three hPSC lines. * pb0.05. hiPSC vs. H9 hESCs.
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Figure 4 Characterization of iMSCs by flow cytometry assay. Overlay images by flow cytometry assay. A: Pluripotent markers
detected with hiPSC (1) and passage 2 iMSC (1). B: typical MSC markers determined with iMSC (1) at passages 2, 5, and 19. The bar
graft presents the quantitative expression of above MSC-markers on iMSC (1) with different passage numbers. C: HLA-ABC and HLA-DL
markers detected with passage 3 iMSC (1). D: CD31, CD34 and CD45 detected with passage 3 iMSC (1).
92 H. Wei et al.(P19) hPSC-derived MSCs expressed typical MSC markers
CD29, CD44, CD73, CD90, and CD105 that typified adult MSCs
(Fig. 4B). Moreover, CD146, a pro-angiogenic marker of MSCs
was found to maintain its expression until late passages(Fig. 4B) even though its expression was known to diminish in
adult MSCs after successive passages in culture Moreover,
low MHC-I marker (HLA-ABC) and no MHC-II marker (HLA-DL)
were detected (Fig. 4C). Furthermore, markers representing
93One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cellsother cell lineages such as CD34 (hematopoietic marker),
CD45 (late leukocyte marker) and CD31 (endothelial marker)
were all undetectable with iMSCs (Fig. 4D) (Covas et al.,
2008). Fig. 4. presents representative data from iMSC (1)
which was derived from the contracting EBs of hiPSC (1). The
surface marker profile of MSCs derived from non-contracting
EBs was shown in Supplementary Fig. 2.
iMSCs were capable of lineage-specific differentiation
Consistent with known MSC characteristics, our hPSC-MSCs
showed adipogenic, osteogenic and chondrogenic differen-
tiation capacity. Fatty droplets and mineralized calcium
deposits were confirmed by Oil red-O (Fig. 5A) and Alizarin
red-S (Fig. 5B) staining respectively. In addition, iMSCs
formed pellets under chondrogenic differentiation condi-
tions and they stained positive for Alcian Blue (Fig. 5C).
iMSCs showed a robust growth potential
Similar to hESC-MSCs, the iMSC lines showed robust growth
kinetic as demonstrated by over 30 cumulative population
doublings in continuous culture without signs of cellular
senescence (Fig. 6A). In comparison, the two BM-MSC linesFigure 5 Multi-potent differentiation of iMSCs. A: hiPSC-MSC (1)
Oil-Red-O Staining. Scale bar: 100 µm. B: hiPSC-MSC (1) at passage 7
Staining. Scale bar: 100 µm. C: Chondrogenesis of iMSC verified by Acould not be expanded to more than passage 9 with a drastic
slowing of growth rates and loss of fibroblastic cellular
morphology. On the other hand, cord blood (CB)-MSCs showed
a self renewal potential closer to iMSCs. Consistently, the robust
proliferation rates of iMSCs coincided with a relatively sustained
telomerase activity which was similar to HeLa tumor cell line or
the pluripotent H9 hESC line (Fig. 6B). In contrast, the parental
line (for hiPSCs) of human dermal fibroblasts (HDF, passage 3)
and BM-MSC (2) showed a diminished telomerase activity.
Furthermore, iMSCs and CB-MSCs displayed a more spindle-
shaped morphology as compared to BM-MSCs (Fig. 6C).iMSCs were safe from tumorigenesis and
cytogenetic abnormalities
In the same teratoma formation experiment which confirmed
the pluripotency of hiPSC (1) and hiPSC (2), passage 2 and 3
iMSCs failed to form teratoma as no tumors were formed and
implanted cells were undetectable by histology assay when
transplanted into renal capsule of SCIDmice (data not shown).
In addition, normal karyotype of iMSCs at young (P10) or later
(P16) passages was confirmed (Fig. 6D).at passage 7 differentiated into adipocyte-like cells verified by
differentiated into osteocyte-like cells verified by Alizarin Red S
lcian blue staining. Scale bar: 50 µm.
Figure 6 Growth kinetics, telomerase activity and karyotype of iMSCs. A: Cumulative population doubling levels (CPDL) from iMSCs,
hESC-MSCs, BM-MSC (1) (from healthy donor) and BM-MSC (2) (from a myocardial infarction patient), and cord blood (CB)-MSC were
recorded and compared. B: Telomerase activity in iMSC (1) of different passages was detected. Human dermal fibroblast (HDF) at
passage 2 and BM-MSCs were used as negative controls while HeLa cell and H9 ES cell were used as positive controls. The arrows on
the right indicate the bands of TRAP products and internal control. C: Morphological comparison of iMSCs, CB-MSCs and BM-MSCs.
D: Normal karyotype observed with iMSC (1) at passages 10 and 16.
94 H. Wei et al.iMSCs showed a marked pro-angiogenic potential
Consistent with previous report of enhanced pro-angiogenic
activity of hiPSC-derived MSCs in comparison to BM-MSCs (Lian
et al., 2010), our iMSCs demonstrated superior angiogenicactivity. When co-cultured with HUVEC, CD146+ sorted iMSCs
promoted more extensive vascular network (Figs. 7A–D) and
more mature tubule formation in length (Fig. 7L) and caliber
of vascular structures as compared to HUVEC alone or co-
Figure 7 Endothelial tube formation assay. HUVECs at passage 3, iMSC (1) at passage 11 and BM-MSC (2) at passage 3 were involved in
this study. A, F: HUVECs only (magnification of 4× and 10×). B, G: HUVECs + iMSC (1) (4× and 10×). C, H: HUVECs + CD44+/CD146+ iMSC (1)
(4× and 10×). D, I: HUVECs + BM-MSC (2) (4× and 10×). E: iMSC (1) only. J: BM-MSCs (2) only. K: Phase contrast and fluorescent images of
HUVECs (CM-Dil labeled, Red) and iMSCs (GFP labelled, green) and overlay. Nuclei were stainedwith DAPI (blue). L: Quantification of tube
length. M: Quantification of tube thickness. * pb0.05, ** pb0.01, MSC+HUVEC vs. HUVEC alone (control). Scale bars: A–E and J, 200 µM;
F–I and K, 100 µM.
95One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cellscultured with unsorted iMSCs. In contrast, BM-MSCs failed to
show either effect. Moreover, there was marked co-
localization of iMSCs as peri-vascular cells in the HUVECs
constituted vascular network (Fig. 7K).
iMSCs showed a marked tissue healing potential
Conditioned medium derived from MSCs is known to contain
important growth factors such as FGF and VEGF (Kinnaird et
al., 2004a, 2004b) that are important for therapeutic effect
of MSCs. Consistent with augmented reparative property,
conditioned medium harvested from our iMSCs induced a
more robust migration of fibroblasts in an in vitro wound
healing model as compared to conditioned media from BM-
MSC or fibroblast alone. There was earlier migratoryresponse and superior ingrowth of fibroblasts into the
created tracks (Fig. 8). Moreover, such effect of iMSC was
sustained even in late passage in culture. The effect of iMSC
(1) conditioned medium on fibroblast wound healing was
shown in Fig. 8.Discussion
Large quantities of CMs and supporting parenchymal cells such
as endothelial cells and smooth muscle cells are needed for
meaningful cardiac cell therapy in post myocardial infarction.
Paracrine effect derived from MSCs play an important role in
cardiac repair by promoting endothelial angiogenesis. Similar
Figure 8 Wound-healing assay. A–D: Human neonatal dermal fibroblasts (passage 8), BM-MSC (2) (passage 4), CB-MSCs (passage 6)
and iMSC (1) (passage 8) were adopted in fibroblast wound-healing assay. Conditioned media containing 2% FBS were collected from
each cell lines after 24 h of culture. Gap area was measured 48-hours after application of conditioned media. E: Quantification of the
gap area. * pb0.05, ** pb0.01, *** pb0.001, BM-MSC, CB-MSCs and iMSC-derived conditioned media vs. fibroblast-derived conditioned
medium as control. ┼ pb0.05, ╫ pb0.01, BM-MSC and CB-MSC derived conditioned media vs. iMSC-derived conditioned medium.
Images were taken by a Leica stereomicroscope.
96 H. Wei et al.to pluripotent hESCs, patient-derived iPSCs can be cryopre-
served and repeatedly used to generate specific cell lineages
such as CMs and MSCs. Given the supportive role of MSCs in cell
therapy, a collective administration of both CMs and MSCsmay
be important for cardiogenesis and angiogenesis for cardiac
repair (Kreutziger et al., 2011).
Currently, hiPSC-CMs and iPSC-MSCs are separately derived
through a laborious process. While cardiac differentiation was
mainly achieved via 3D EBs formation, hESCs and hiPSCswere 2D
differentiated to MSCs, FACS sorted and may even clonally
derived through single cell dilution to yield homogenous
population of MSCs (Lian et al., 2007). In this study, we
demonstrated that using a CARM/SB cardiac differentiation
protocol (a serum-free insulin-free cardiac differentiation
medium supplemented with a specific inhibitor for the p38
MAPK, SB203580 (Graichen et al., 2008), CMs and MSCs were
simultaneously derived from a single cardiac differentiation
experiment. While CMs can be obtained from contracting EBs,
MSCs can be derived from both contracting and non contracting
EBs. Comparing to the CARM/SB protocol which consistently
yielded homogenous iMSCs from the outgrowth of EB aggregatesplated, another well-adopted serum containing cardiac differ-
entiation protocol which uses 20% serum and the EB aggregates
were plated early after EB formation, hereby named EB-20
(Kehat et al., 2001) method, yielded marginally lower cardiac
differentiation efficiency, but failed to generate homogenous
MSCs even after repeated passages in culture (data not shown).
Thus we speculate that the successful generation of
homogenous MSCs by CARM/SB protocol could be due to
several factors: 1) insulin‐free differentiation medium known
to favor the formation of mesoderm (Freund et al., 2008), 2)
serum‐free differentiation medium may prevent excessive
outgrow of mixed cell lineages from three germ layers, and 3)
prolonged suspension culturing of EB aggregates (till 15 days)
may withhold excessive growth of various cell lineages.
Our iMSCs meet the criteria for human MSCs set by the
Mesenchymal and Tissue Stem Cell Committee of the
International Society for Cellular Therapy (Dominici et al.,
2006). Our iMSCs were multipotent and expressed typical MSC
markers (CD29, CD44, CD73, CD90, and CD105), but express no
endothelial marker CD31 neither hematopoietic markers CD45
and CD34 associated with bone marrow-derived cells.
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therapy since cell loss during and after cell transplantation is
substantial. However, due to the limited self-renewal poten-
tial and lower functional potency associated with aging and
chronic diseases, only human MSCs with a passage number less
than 6 might retain sufficient reparative capacity (Briquet et
al., 2010; Li et al., 2008). Furthermore, clinical trials indicated
that as much as 107–108 or 5×106/kg MSCs would have to be
prepared for clinical application (Chen et al., 2004; Macmillan
et al., 2009). In addition, repeated generation of large
numbers of young and functional-specific subpopulation of
MSCs may be needed to sustain therapeutic efficacy in repeat
injections. However, single aspiration of bone marrow may
only yield sufficient MSCs for one time cell delivery and such
yield is greatly insufficient for isolation of functional sub-
populations. In contrast, large quantities of iMSCs (as
compared to BM-MSCs) could be generated from hiPSCs and
our iMSCs showed robust self-renewal potential that is
consistent with previously reported hESC-MSCs and hiPSC-
MSCs (Hwang et al., 2008; Lian et al., 2007).
The safety of iMSCs remains to be a major concern for
clinical application since they are derived from pluripotent
iPSCs with prolonged culture period. Our iMSCs showed no
expression of SSEA-4, TRA-1-60 and TRA-1-81 and no
teratoma formation despite obviating FACS sorting or the
derivation of single cell colonies (Lian et al., 2007). Our
data suggest that such iMSCs derived with the CARM/SB
protocol are free of pluripotent stem cell contamination
and could maintain a normal karyotype after culture
expansion.
Pro-angiogenic effect of MSCs has been documented in
post-MI cardiac repair (Amado et al., 2005) and ischemic
limbs (Lian et al., 2010). MSCs have been suggested to
function as pericytes or perivascular cells in supporting
endothelial cell to form vascular networks (Covas et al.,
2008; Crisan et al., 2008; Schugar et al., 2009) in which MSCs
are indispensable for forming functionally competent vas-
culature without leakage (Kreutziger et al., 2011). Consis-
tently, our results showed that iMSCs acted cooperatively
with HUVECs to form extensive tube-like vascular structures
further supporting their perivascular role in angiogenesis.
Furthermore, our iMSCs retained stronger pro-angiogenic
effect at passage 12 than BM-MSCs at passage 3. In addition,
the CD44+/146+ sorted iMSCs showed a stronger pro-
angiogenic effect than unsorted iMSCs. Consistent with
pro-wound healing effect of MSCs (Walter et al., 2010; Wu
et al., 2007), our iMSCs demonstrated a superb healing
effect in promoting cellular migration and tissue coales-
cence than that of BM-MSCs. Collectively, our iMSCs exhibit
substantial paracrine protective effects that may well
support substantial tissue repair when transplanted togeth-
er with concurrently generated CMs for autologous cell
therapy.
Materials and methods
Generation and characterization of human
pluripotent stem cell lines
Human iPSC lines, hiPSC (1) and hiPSC (2), were generated in
our laboratory from human neonatal dermal fibroblasts(ATCC) via retroviral-based reprogramming with Yamanaka
factors (OCT-4, SOX-2, c-Myc and KLF-4) (Takahashi et al.,
2007) . In addition, a human embryonic stem cell (hESC) line
(H9), acquired from WiCell Institute, Wisconsin, USA, was
adopted as control.
Immunocytochemistry
hiPSCs grown on feeder cells were fixed and permeabilized
and subjected to immunocytochemistry assay with mAbs
against OCT-4, SSEA-4, TRA 1–60, and TRA 1–81 (Millipore).
Laser confocal microscopic images were taken with Carl Zeiss
510 microscope.
RT-PCR and genomic DNA PCR
RNA was extracted from H9 hESCs, hiPSC(1), hiPSC (2),
hiPSC (1) and (2)-derived EBs and the parental HDF. Next,
first-strain cDNA was synthesized using oligo dTs from 1 μg of
total RNA. Endogenous and transgene expression of OCT-4,
SOX-2, c-MYC and KLF-4 genes were amplified by semi-
quantitative RT-PCR. Moreover, genomic DNA was extracted
from H9 hESCs, hiPSC (1), hiPSC (2), iMSC (1), and the
parental HDF. OCT-4, SOX-2, c-MYC and KLF-4 transgenes
were amplified by genomic DNA PCR. Two sets of primers
were used. The 1st was for the endogenous gene RT-PCR and
the 2nd was for both of the transgene RT-PCR and genomic
DNA PCR. All primers and PCR conditions used in this study
were adopted from a previous report (Takahashi et al.,
2007).
Teratoma formation
Approximately 2×106 of hiPSC (1) and (2) were injected into
the kidney capsule and hindlimb muscle of female NOD-SCID
mice for 12 weeks. Tumors were explanted, fixed, paraffin
embedded and sections were stained with haematoxylin and
eosin.
Karyotyping
Chromosomal studies were carried out in the Cytogenetic
Lab of KK Women and Children Hospital, Singapore. Standard
G-banding chromosome analysis was performed with hiPSC
(1) and hiPSC (2) using standard protocols for high resolution
G-banding.
Generation of hiPSC-CMs and hiPSC-MSCs
Prior to differentiation, hiPSCs and hESCs were maintained on
mitomycin C-treated mouse embryonic fibroblasts (MEF)
feeder in hESC medium (final concentration: 80% Knockout
DMEM, 20% Serum replacement, 1% non-essential amino acid,
1 mM L-glutamine, 0.1 mM beta-mercaptoethanol and 4 ng/ml
basic Fibroblasts Growth Factor (bFGF), all from Invitrogen).
Cardiac differentiation was performed by the CARM/SB
differentiation procedure (Graichen et al., 2008): On Day 1, EBs
were formed mechanically from hESC/hiPSC colonies and
transferred into 6-well non-adherent dishes and cultured in
hESC medium without bFGF for 24 h. On Day 2, the CM/MSC
differentiation were initiated with a serum-free and insulin-
free medium, CARM (DMEM High Glucose 485 ml, L-glutamine
5 ml, NEAA 5 ml, Selenium Transferrin 5 ml (Sigma) and 2-
mercaptoethanol 3.5 μl) supplemented with SB 203580 (5 μM),
a specific p38-MAPK inhibitor (Sigma) and kept for 4 days till
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maintained till Day 14. EB aggregates were plated on 0.1%
gelatin-coated 6-well plate or 3.5 cm petri dishes in DMEM
medium containing 2% FBS and kept for 1 week. Contracting EB
aggregates emerged from Days 15 to 21. Next, the contracting
CM clumps were dissected out. In addition, H9 hESC, hiPSC (1)
and (2) were also differentiated with the EB-20 method (Kehat
et al., 2001; Zhang et al., 2009) in which the EB aggregates
were plated on Day 8 before contracting EBs emerged.
Contracting and non-contracting Day 15 EBs from the same
differentiation experiment were fixed with 4% paraformalde-
hyde (PFA) and permeabilized with 0.1% Triton X-100 and co-
stained with a polyclonal antibody against human cardiac
myosin light chain (MLC), (rabbit anti-human MLC), a specific
CMs marker from Abcam (phospho S20) antibody (ab2480))
followed by a second antibody (Alexa Fluo® 488 goat anti-
rabbit IgG, Invitrogen), and anti-CD44, a MSC marker from BD
Cat#550392. Followed by a second antibody (Alexa Fluo® 555
Donkey anti-mouse IgG, Invitrogen).
EBs dissociation and quantitative assays for CMs and MSCs
in EBs
Day 15 EBs were dissociated in 0.1% Trypsin as and seeded
on glass coverslips with a density of 5×105 cells/cm2 with a
cytospin approach as previously described (Zweigerdt et al.,
2003). Cells were fixed and permeabilized as above
mentioned. Next, cells from different slides were incubated
with the primary antibodies against β-MHC (Alexis Bio-
chemicals, FL, USA), or CD44 followed by second antibody
(Alexa Fluo® 555 Donkey anti-mouse IgG from Invitrogen).
Cells were counter-stained with DAPI for nuclear staining
and examined on a Zeiss LSM 710 Microscope.
Isolation and expansion of hiPSC-MSCs
As shown in Fig. 2A, following the CARM/SB method, rapid
outgrowth of MSC-like cells from the attached EB aggregates
were observed immediately after plating. Those MSC-like
cells migrated out and covered N80% of a well of 6-well plate
in two weeks time. After mechanical removing CM clumps
and other non-MSC-like cells, the remaining MSC-like cells
were cultured in MSC medium (DMED supplemented with 10%
serum) to full confluency and dissociated with trypsin and
transferred into a T25 flask (Passage 1). Cells were further
expanded in MSC medium with a 1:4 split ratio. MSCs were
continually expanded to passage 20 and above.
Characterization of hiPSC-CMs
Clumps of contracting CMs were dissected out under a
microscope and were enzymatically dissociated (Maltsev et
al., 1994). The cardiac marker expression of hiPSC-CMs was
determined by immunocytochemistry assay. Dissociated
cardiomyocytes were continually cultured in DMEM+2% FBS
for 2 more weeks before characterization.
Immunofluorescent characterization of cardiac markers
The prepared cardiomyocytes were seeded on glass coverslips
and immunocytochemically stained for cardiac markers with
antibodies against cardiac sarcomeric α-actinin (clone EA-35.
Sigma) and β-MHC (Alexis Biochemicals, FL, USA), followed by
Alexa Fluo® 488 goat anti-rabbit IgG (Invitrogen, CA, USA);and cardiac titin (1:10) (Sigma-Alrich, MO, USA) followed by
Alexa Fluo® 555 donkey anti-rabbit IgG. All cardiomyocytes
tested in this study were ~5 weeks post differentiation.
Electrophysiological characterization of cardiomyocytes
Dissociated CMs were seeded on uncoated 3.5 cm petri dishes
and were transferred to a recording chamber mounted on the
stage of an inverted microscope (TE2000-S, Nikon, Tokyo,
Japan). Whole-cell action potential (APs) was recorded with a
Patch-Clamp amplifier (Axon 200B, Axon Instruments). Data
acquisition and analysis were performed using Clampex and
Clampfit software (version 10.0, Axon Instruments). In the
current-clampmode, the APs were recorded in normal Tyrode's
solution. Ventricular-like, atrial-like and nodal-like-CM were
identified by their characteristic action potential (AP) proper-
ties including AP amplitude, AD duration and maximum rate of
depolarization (dV/dtmax).
Characterization of hiPSC-MSCs
hiPSC (1) and hiPSC (2) derived-MSCs, labeled as iMSC (1) and
iMSC (2), respectively, were thoroughly characterized. Two
lines of human bone marrow (BM)-derived MSCs were used in
this study as control. BM-MSC (1) was derived from marrow
mononuclear cells (DV Biologics, Costa Mesa, CA). BM-MSC
(2) and CB-MSCs were derived from the bone marrow of a
myocardial infarction patient recruited at National Heart
Centre Singapore, and healthy umbilical cord blood respec-
tively, following protocols approved by the Institutional
Review Board of Singapore General Hospital.
Surface markers measurement and cell sorting
The derived iMSC (1), iMSC (2) and hESC-MSCs, BM-MSCs and
cord blood-MSC (CD-MSCs) were analyzed by flow cytometry
with a BD Aria II system. PE, APC and FITC congregated mAbs
(all from BD Biosciences) were used to determine CD29, CD44,
CD73, CD90, CD105, CD146, CD31, CD34 and CD45 expression.
CD44+/CD146+ hiPSC-MSCs were sorted out by fluorescent-
activated cell sorting (FACS). Moreover, pluripotent stem cell
markers SSEA-4, TRA-1-60, TRA-1-81 (Primary antibodies from
Millipore) and MHC Class I and II markers, HLA-AC and HLA-DL
(BD Biosciences) were determined.
Multi-potent differentiation of iMSCs
Adipogenic and osteogenic differentiation of iMSCs. Passage 6
iMSC (1) were differentiated into adipocytes and osteocytes in
the corresponding differentiation media from Stemcell Tech-
nologies®. The adipocytes and osteocytes were confirmed by
Oil-Red-O staining and Alizarin Red S staining respectively.
Chondrogenic differentiation of iMSCs. Passage 3 iMSC (1)was
differentiated into chondrocytes using STEMPRO Chondrogenesis
Differentiation Kit (GIBCO). Alcian Blue Staining was conducted
on cell pellet 18 days after differentiation.
Growth kinetics of iMSCs. iMSC (1), iMSC (2), H3 hESCs, BM-
MSCs and CB-MSCs were serially cultured to Passage 20. After
Passage 2, iMSCs were expanded with a starting density of
1×106 cells per T75 flasks in MSC medium. Cells were
subcultured when they reached 90% confluence. The growth
99One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cellskinetics of MSCs derived from two bone marrow samples was
similarly determined. The cumulated population doublings
level (NPDL) was calculated and plotted.
Telomerase activity assay. The telomerase activity of
cultured cells was explored using TRAPEZE telomerase detection
kit (Millipore) as described (Kim et al., 1994). Cell extracts (from
a total of 5×106) was prepared from iMSCs, BM-MSCs, human
dermal fibroblasts, HeLa cell and H9 ESCs using 3-[(3-cholami-
dopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS) lysis
buffer. Detection of telomerase activity in cells was carried out
by the PCR-based telomeric-repeat amplification protocol
(TRAP).
Teratoma formation assay. See above section of hiPSC
teratoma formation assay. In the same teratoma formation
experiment for hiPSCs, a total of 2×106 of passage 2 and 3
iMSCs were injected intramuscularly into the hindlimb and
kidney capsule of female NOD-SCID mice for 16 weeks to
form teratoma.
Karyotyping. The cytogenetic stability of iMSCs was mon-
itored by karyotyping by the Cytogenetic Lab of KK Women
and Children Hospital Singapore following standard protocols
for high resolution G-banding.
Matrigel-based tube formation assay. Matrigel (BD 8482) of
75 μL was added in each well of a 96-well plate. Unsorted and
CD44+/CD146+ iPSC-MSCs (P6-P11) and unsorted BM-MSCs
(P3), with a total number of 0.6×104, were seeded on Matrigel
together with 1.25×104 human umbilical vein endothelial
cells (HUVECs) (Invitrogen) at P3–4. After 24 h, vessel-like
network structureswere examined under lightmicroscopy and
images were taken. Co-localization of HUVECs and iPSC-MSCs
were confirmed by fluorescent microscopy of pre-labeled
HUVECs (CM-Dil) and iPSC-MSCs (Lentiviral vector expressing
GFP). With each experiment, triplicated wells were set for
different conditions and three independent experiments were
performed. The average data of triplicated wells was
calculated and data from three independent experiments
was plotted as bar-graft (mean% ±SD). Tube formation [total
tube length (mm)/high-powered field (mm2)] was quantified
using ImageJ software (NIH).
Wound-healing assay. Human neonatal dermal fibroblasts
(P8) were cultured to 90% confluence and a 2-mm wide track
was physically created by a cell scraper. The conditioned-
media (CMed) of iMSC, iMSC (P6) and BM-MSC (P4) were
collected after 24 h incubating in serum-free DMEM and
added to the wounded monolayer of fibroblasts and
incubated for 24 h. With each experiment, triplicated wells
were set for different conditions and three independent
experiments were performed. The average data of triplicat-
ed wells was calculated and data from three independent
experiments was plotted as bar-graft (mean±SD). Images
were acquired with a light microscope (BX51, Olympus) and
digital camera (Moticam 1000, Moticam). The gap area
(mm2) was quantified using ImageJ software (NIH) by scale
set at 300 pixel/mm.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.scr.2012.04.003.Statistical analysis
Data were expressed as mean±SD and analyzed by 2-tailed
Student t tests. A p values below 0.05 were considered to be
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